notion
type
interferon
possess
antiinflammatori
potenti
support
data
clinic
applic
multipl
sclerosi
studi
cultur
immunecompet
cell
investig
experiment
diseas
whole
anim
observ
deserv
attent
virologist
potenti
role
pathogenesi
clinic
manag
viru
infect
biolog
role
interferon
confin
defenc
viru
infect
one
thing
infect
microb
virus
appear
induc
interferon
product
interferon
prove
abl
protect
experiment
anim
infect
nonvir
agent
moreov
vitro
studi
document
varieti
biolog
activ
interferon
includ
abil
inhibit
divis
certain
tumour
cell
line
activ
cytolyt
potenti
nk
cell
lymphocyt
enhanc
mhc
molecul
express
togeth
properti
made
interferon
becom
recogn
key
compon
innat
immun
activ
innat
immun
manifest
mani
way
promin
one
inflamm
acut
inflamm
defin
combin
vascular
chang
mainli
vasodil
increas
vascular
permeabl
chang
endotheli
adher
properti
sometim
intravascular
blood
clot
follow
disrupt
blood
vessel
bleed
ii
transud
fluid
caus
oedemat
swell
iii
exud
activ
diapedesi
leukocyt
vessel
caus
cellular
infiltr
indur
inflam
tissu
chronic
inflamm
characterist
persist
lowgrad
exposur
inflammatori
agent
intermitt
vascular
chang
oedema
usual
less
pronounc
cellular
infiltr
may
develop
extens
granuloma
initi
fibrou
scar
tissu
caus
destruct
deform
organ
bone
cartilag
kidney
lung
etc
local
organspecif
inflamm
mostli
accompani
metabol
haematopoiet
chang
result
alter
level
circul
leukocyt
hypertrophi
chang
architectur
lymphoid
organ
alter
level
certain
protein
acutephas
reactant
plasma
given
earli
recognit
key
role
interferon
innat
immun
common
knowledg
inflamm
promin
manifest
innat
immun
somewhat
surpris
see
except
report
explor
role
interferon
aspecif
inflamm
initi
mid
instead
earli
focu
explor
nonantivir
effect
antitumour
cell
effect
regul
b
cell
immun
activ
perceiv
offer
perspect
overal
boost
immun
defenc
cancer
time
inflamm
research
address
granulocyt
rather
lymphocyt
biolog
commun
littl
interact
interferon
worker
discoveri
andor
character
mani
cytokin
tnf
chemokin
nonantivir
action
interferon
gradual
came
seen
sector
cytokin
network
control
respons
innat
well
acquir
immun
laboratori
head
peter
de
somer
pioneer
product
cultiv
human
skin
fibroblast
van
damm
billiau
enterpris
led
first
clinic
trial
interferon
fever
reaction
skin
inflamm
de
somer
et
al
elicit
interferon
inject
patient
made
us
becom
interest
role
interferon
inflamm
line
investig
would
lead
us
isol
character
novel
inflammatori
mediat
coinduc
interferon
interact
interferon
name
cytokin
van
damm
et
al
companion
cytokin
strong
pyrogen
van
damm
et
al
chemokin
granulocytechemotact
van
damm
et
al
proost
et
al
monocytechemotact
protein
van
damm
et
al
laboratori
involv
inflamm
complet
investig
matrix
metalloproteas
mmp
interact
cytokin
chemokin
review
old
recent
work
role
type
interferon
inflamm
type
ii
interferon
refer
reader
earlier
review
role
inflammatori
reaction
local
system
reaction
toward
lipopolysaccharid
billiau
vandekerckhov
acut
system
inflamm
accompani
experiment
autoimmun
diseas
make
use
freund
adjuv
matthi
et
al
earli
studi
koltai
mec
use
carrageenin
footpad
swell
reaction
studi
inflammatori
antiinflammatori
influenc
interferon
interferon
induc
polyri
rc
mycophagederiv
doublestrand
rna
semliki
forest
viru
observ
indic
interferon
semipurifi
mous
unit
iv
h
carrageenin
challeng
exert
signific
modest
antiinflammatori
effect
reduct
footpad
swell
induc
also
inhibit
respons
degre
inhibit
well
correl
level
circul
interferon
lead
author
suggest
effect
due
induc
mediat
similar
studi
use
lp
instead
carrageenin
footpad
respons
found
suppress
acut
phase
infect
lactic
dehydrogenas
viru
follow
bolu
intraven
inject
newcastl
diseas
viru
hereman
et
al
virus
potent
induc
system
mice
interferon
instrument
bring
suppress
evid
demonstr
could
partial
undon
prior
administr
neutral
antibodi
direct
mous
inflammatori
respons
could
also
inhibit
give
mice
seri
intraperiton
inject
interferon
start
shortli
lp
challeng
hereman
et
al
degre
inhibit
dosedepend
requir
least
unitsmous
given
daili
day
rel
lp
inject
inhibit
observ
natur
recombin
remark
also
recombin
veldhui
et
al
show
system
administr
protect
rat
inflammatori
brain
damag
due
experiment
induc
transient
ischemia
protect
evid
diminish
infiltr
neutrophil
reduc
disrupt
bloodbrain
barrier
bbb
similar
treatment
also
provid
complet
protect
neutrophil
infiltr
bbb
disrupt
follow
local
inject
recombin
rat
veldhui
et
al
overexpress
brain
region
upregul
reduc
ifntreat
anim
lead
author
dismiss
effect
express
explan
protect
action
possibl
mechan
consid
worker
inhibit
gelatinas
b
product
releas
zymographi
show
presenc
inject
brain
region
significantli
deplet
anim
neutrophil
inject
well
treatment
prevent
disrupt
bbb
appear
model
propos
neutrophil
need
autocrin
order
abl
disrupt
transgress
bbb
local
inject
consid
stimul
inhibitor
secret
neutrophil
protect
effect
collageninduc
arthriti
mice
shown
studi
mice
receiv
singl
inject
syngen
fibroblast
carri
retroviru
express
murin
triantaphyllopoulo
et
al
protect
accompani
lower
total
anticollagen
igg
level
lower
anticollagen
higher
level
vitro
inhibit
collageninduc
secret
lymph
node
cell
reduc
level
produc
bone
marrowderiv
macrophag
triantaphyllopoulo
et
al
similarli
treatment
daili
inject
found
protect
mice
collageninduc
arthriti
evid
macroscop
histopatholog
biochem
paramet
van
holten
et
al
particular
relev
reduct
number
osteoclast
suggest
inhibit
osteoclastogenesi
immunohistochem
examin
inflam
joint
tissu
reveal
ca
reduc
express
express
also
tend
lower
express
convers
doubl
protect
effect
type
interferon
collageninduc
arthriti
echo
similar
effect
type
ii
interferon
model
rat
activ
adopt
transfer
form
eae
report
inhibit
system
administr
induct
phase
experiment
procedur
natur
highli
purifi
type
interferon
abreu
hertz
degheni
abreu
et
al
similar
protect
effect
report
eae
induc
sjlj
mice
billiau
et
al
yu
et
al
addit
infect
mice
lactic
dehydrogenas
viru
known
act
strong
induc
transient
interferon
product
similar
protect
effect
murin
model
billiau
et
al
inada
mim
earli
de
maeyer
et
al
report
inhibitori
effect
passiv
administ
activ
induc
inflammatori
respons
elicit
presensit
mice
celldepend
antigen
sheep
red
blood
cell
newcastl
diseas
viru
de
maeyer
et
al
de
maeyer
gresser
et
al
author
also
found
treatment
high
dose
prolong
surviv
skin
graft
done
across
mhc
barrier
mice
worker
could
confirm
observ
hirsch
et
al
other
work
smaller
dose
interferon
found
opposit
effect
skurkovich
et
al
discuss
de
maeyer
de
maeyerguignard
low
level
system
interferon
might
enhanc
high
level
might
inhibit
graft
reject
gener
accept
use
type
interferon
treat
viru
infect
man
limit
use
patient
chronic
hepat
b
c
current
combin
pegyl
interferon
ribavirin
recommend
treatment
persist
hcv
infect
accompani
liver
inflamm
incipi
fibrosi
sustain
viral
respons
achiev
case
review
see
ward
kugelma
pegyl
also
treatment
choic
reportedli
superior
lamivudin
chronic
hbv
infect
viral
respons
accompani
variabl
degre
improv
liver
function
reduct
inflammatori
chang
liver
case
hcvassoci
chronic
liver
diseas
evid
accumul
applic
interferonbas
treatment
schedul
also
result
delay
develop
hcvassoci
hepatocellular
carcinoma
camma
et
al
azzaroli
et
al
soga
et
al
omata
et
al
benefici
effect
liver
histolog
function
probabl
result
part
direct
effect
interferon
viral
replic
activ
howev
antiinflammatori
immunomodulatori
activ
interferon
might
also
contribut
respect
provid
direct
tissu
protect
andor
adequ
viral
antigenspecif
immun
respons
carotenuto
et
al
hypothes
interferon
boost
antivir
respons
modifi
function
intrahepat
antigenpres
cell
order
separ
effect
consequ
direct
antivir
effect
examin
chang
intrahepat
apc
cell
interferon
treatment
patient
whose
viral
load
alreadi
reduc
treatment
lamivudin
therapi
express
kupffer
cell
liver
biopsi
increas
simultan
serum
level
solubl
also
increas
effect
consid
indic
promot
differenti
myeloid
dendrit
cell
effect
also
report
occur
vitro
system
time
cell
infiltr
portal
space
reduc
mainli
due
drastic
decreas
number
cell
author
note
cell
infiltr
liver
gener
concern
nonantigenspecif
bystand
cell
depend
presenc
increas
level
matrix
metalloproteas
henc
specul
deplet
cell
therapi
effect
independ
hepat
apc
may
due
reduct
releas
matrixdegrad
metalloproteas
studi
howev
indic
increas
intrahepat
lymphocyt
count
import
viral
respons
tang
et
al
longterm
treatment
patient
relapsingremit
ms
gener
recogn
reduc
frequenc
relaps
document
gadoliniumenhanc
mri
would
far
strongest
support
evid
antiinflammatori
andor
immunosuppress
potenti
interferon
mechan
treatment
protect
integr
bloodbrain
barrier
remain
unclear
monitor
immunolog
marker
ms
patient
cours
treatment
shed
light
mechan
may
involv
calabresi
et
al
report
increas
level
solubl
soon
initi
therapi
calabresi
et
al
vitro
studi
vide
infra
author
propos
treatment
induc
convers
membranebound
solubl
concomitantli
increas
level
express
counterreceptor
lymphocyt
decreas
calabresi
et
al
vitro
treatment
lymphocyt
reproduc
effect
though
treatment
reduc
express
author
propos
follow
treatment
patient
increas
solubl
caus
downregul
net
effect
inhibit
adhes
interact
lymphocyt
brain
endotheli
cell
vivo
studi
demonstr
vitro
action
biolog
take
place
vivo
howev
whether
inde
modul
inflamm
accompani
tissu
damag
remain
prove
evid
affect
cours
ms
inhibit
product
andor
activ
proteas
come
mainli
studi
blood
monocyt
gveric
et
al
well
monocytederiv
dendrit
cell
kouwenhoven
et
al
ms
patient
reportedli
express
higher
normal
level
also
serum
level
enzym
increas
waubant
et
al
liuzzi
et
al
duboi
et
al
sever
independ
studi
treatment
associ
decreas
serum
andor
increas
level
trojano
et
al
waubant
et
al
giannelli
et
al
waubant
et
al
yushchenko
et
al
karabudak
et
al
avolio
et
al
express
enzym
leukocyt
similarli
affect
galboiz
et
al
gilli
et
al
togeth
observ
led
author
postul
exert
benefici
influenc
shift
balanc
proteas
inhibitor
unresolv
question
stage
lesion
develop
proteas
activ
interven
essenti
leukocyt
abl
infiltr
cn
play
role
disrupt
bbb
consequ
play
role
degrad
myelin
type
interferon
play
import
role
dendrit
cell
biolog
lead
author
consid
potenti
adjuv
dendrit
cellbas
vaccin
santini
et
al
dendrit
cell
gener
vitro
peripher
blood
monocyt
presenc
type
interferon
properti
differ
dendrit
cell
gener
classic
combin
gmcsf
plu
santini
et
al
presenc
matur
dendrit
cell
progress
rapidli
result
cell
gener
potent
exert
antigenpres
activ
eg
use
mix
leukocyt
reaction
apc
prime
specif
antigen
cytokin
secret
profil
also
distinct
product
may
low
santini
et
al
detournay
et
al
product
level
high
shown
instrument
enhanc
mlr
act
antagonist
suppressor
cell
detournay
et
al
murin
dendrit
cell
deriv
vitro
bone
marrow
cell
isol
spleen
express
type
interferon
suggest
autocrin
posit
feedback
loop
oper
dendrit
cell
matur
montoya
et
al
santodonato
et
al
use
prime
ebv
antigen
compar
function
activ
dendrit
cell
induc
gmcsf
plu
either
dendrit
cell
gener
presenc
trigger
stronger
cellular
expans
convey
higher
level
cytotox
lymphocyt
ebv
antigencarri
cell
similar
observ
report
carbonneil
et
al
show
dendrit
cell
gener
presenc
express
higher
level
mhc
class
molecul
produc
similar
higher
level
follow
ligat
stimul
superantigen
cell
express
low
level
dcsign
hiv
antigenpuls
cell
abl
activ
cell
hivneg
donor
produc
mount
cytotox
activ
target
cell
express
hiv
antigen
type
interferon
also
found
inhibit
secret
dendrit
cell
vide
infra
et
al
vivo
signific
variou
find
remain
defin
possibl
dendrit
cell
phenotyp
function
properti
gener
vitro
presenc
type
interferon
form
distinct
subpopul
occur
transient
vivo
acut
phase
viru
infect
could
repres
import
player
make
link
innat
acquir
immun
viru
antigen
present
sole
prerog
dendrit
cell
central
nervou
system
astrocyt
express
mhc
class
ii
molecul
tightli
control
fashion
wherebi
strong
induc
astrocytoma
cell
line
type
interferon
describ
inhibit
mhc
class
ii
molecul
induct
ransohoff
et
al
devajyothi
et
al
corsini
et
al
report
longterm
month
shortterm
h
treatment
ms
patient
associ
decreas
adhes
pbmc
cultur
human
umbil
vein
endotheli
cell
vitro
type
exposur
result
increas
serum
level
solubl
treatment
cultur
endotheli
cell
fail
affect
express
antagon
induc
overexpress
hladr
antigen
howev
subsequ
studi
indic
vitro
exposur
inhibit
basal
express
cultur
human
umbil
vein
endotheli
cell
human
brainderiv
microvascular
endotheli
cell
bmec
defazio
et
al
overexpress
cultur
bmec
follow
exposur
also
report
counteract
defazio
et
al
report
treatment
patient
induc
increas
level
solubl
corsini
et
al
subsequ
confirm
echo
vitro
studi
calabresi
et
al
show
cocultur
bmec
cell
induc
vcam
express
cell
membran
rapidli
follow
shed
solubl
vcam
overexpress
mediat
part
activ
tnf
receptor
could
abrog
addit
solubl
tnf
receptor
solubl
adhes
molecul
may
interfer
adhes
leukocyt
residu
membranebound
adhes
molecul
togeth
observ
seem
indic
type
interferon
produc
within
inflammatori
foci
inhibit
express
adhes
molecul
surfac
endotheli
cell
stimul
releas
solubl
form
cellular
environ
may
lead
reduc
adhes
leukocyt
endotheli
line
blood
vessel
henc
attenu
inflammatori
reaction
mechan
invok
explain
protect
action
relaps
remit
ms
corsini
et
al
defazio
et
al
calabresi
et
al
increas
extracellular
proteolysi
key
element
pathogenesi
inflamm
unbalanc
product
proteas
inhibitor
account
structur
tissu
damag
demyelin
cytolysi
desintegr
basement
membran
also
facilit
leukocyt
infiltr
gener
autoantigen
regul
activ
cytokin
chemokin
review
see
cuzner
opdenakk
amongst
extracellular
proteas
particularli
well
studi
stuve
et
al
found
antagon
chemokin
rant
stimul
migrat
peripher
blood
mononuclear
cell
across
fibronectin
matrix
abrog
chemokineinduc
elev
mrna
level
secret
inhibit
product
also
seen
human
peripher
blood
mononuclear
cell
human
umbil
vein
endotheli
cell
stimul
platelet
endotheli
cell
adhes
ligat
nelissen
et
al
similar
studi
employ
dendrit
cell
gener
vitro
incub
human
blood
monocyt
gmcsf
plu
et
al
deserv
special
mention
show
inhibit
secret
also
demonstr
net
inhibitori
effect
total
proteas
load
ie
balanc
inhibitor
revers
hit
back
caus
proteolyt
degrad
abolish
activ
effect
may
impact
effect
therapi
ms
human
lymphocyt
stimul
assay
report
inhibit
cellular
prolifer
modifi
express
membran
receptor
cytokin
secret
noronha
et
al
rep
et
al
upregul
affect
induct
stimul
tand
blymphocyt
block
secret
inhibit
wherea
secret
unaffect
secret
increas
twofold
nearli
fourfold
addit
studi
rapidli
upregul
express
prime
unprim
cell
augment
releas
cultur
supernat
fluid
rep
et
al
ms
patient
treat
serum
level
increas
transient
similar
chang
seen
monocyt
cultur
treatment
also
result
initi
rise
mean
percentag
cell
gradual
increas
mean
level
solubl
plasma
rep
et
al
inhibit
product
stimul
lymphocyt
confirm
studi
employ
murin
preimmun
lymph
node
cell
bovin
collagen
antigen
triantaphyllopoulo
et
al
activ
mononuclear
phagocyt
produc
mani
cytokin
amongst
gener
consid
import
proinflammatori
factor
activ
mpc
result
stimul
foreign
agent
combin
endogen
macrophageactiv
factor
import
alia
type
ii
interferon
unexpectedli
type
ii
interferon
shown
enhanc
product
activ
mpc
svederski
et
al
though
type
interferon
first
believ
possess
similar
potenti
effect
product
wallach
later
studi
abukhabar
et
al
demonstr
rather
inhibit
product
mitogenactiv
human
pbmc
similar
inhibitori
effect
seen
lp
induc
receptor
antagonist
whole
human
blood
vitro
huang
et
al
also
studi
effect
collageninduc
arthriti
mice
found
reduc
level
produc
vitro
bone
marrowderiv
macrophag
triantaphyllopoulo
et
al
phagocytosi
apoptot
cell
particular
apoptot
cell
import
control
inflamm
significantli
mononuclear
phagocyt
engag
process
rather
activ
downregul
term
cytokin
product
magnu
et
al
system
consist
rat
microglia
ingest
apoptot
encephalitogen
lymphocyt
found
enhanc
phagocyt
activ
without
affect
downregul
cytokin
product
chan
et
al
suppress
haematopoiesi
common
find
clinic
studi
type
interferon
wong
et
al
schmid
et
al
peckradosavljev
et
al
suppress
concern
erythropoiesi
well
leukopoiesi
thrombopoiesi
acut
inflamm
mostli
associ
myelopoiet
burst
respons
increas
blood
leukocyt
count
contribut
infiltr
local
inflammatori
site
leukocyt
myelosuppress
effect
interferon
produc
inflammatori
reaction
might
therefor
mitig
system
respons
well
leukocyt
infiltr
local
inflammatori
site
type
interferon
inform
support
propos
seem
avail
howev
case
studi
mice
shown
endogen
power
downregul
myelopoiesi
elicit
inflammatori
stimuli
ablat
administr
neutral
antibodi
gene
knockout
result
sever
inflammatori
reaction
matthi
et
al
data
review
see
summari
tabl
appear
type
interferon
exert
sever
cellular
effect
may
endow
overal
antiinflammatori
activ
mani
observ
support
conclus
done
context
need
provid
explan
gener
recogn
benefici
effect
therapi
rrm
howev
vivo
anim
model
inflammatori
reaction
diseas
strong
inflammatori
compon
type
interferon
confirm
provid
least
partial
protect
final
evid
avail
suggest
also
chronic
viral
hepat
part
benefici
effect
type
interferon
therapi
may
well
account
antiinflammatori
effect
leukocyt
traffic
within
lymphoid
organ
organ
inflam
tissu
foremost
import
featur
acut
inflamm
serv
purpos
immedi
earli
defenc
local
insult
typic
innat
immun
also
essenti
adequ
develop
later
adapt
immun
instanc
whether
adapt
respons
assum
charact
depend
larg
assort
leukocyt
cytokin
chemokin
particip
preced
acut
inflamm
given
observ
potenti
regul
recruit
well
secretori
activ
leukocyt
inflamm
follow
may
also
particip
regul
adapt
immun
respons
may
part
explan
observ
mice
rat
treatment
modifi
cours
experiment
diseas
complex
pathogenesi
eae
cia
skin
graft
accept
interest
thought
type
interferon
evolv
becom
signal
activ
intracellular
tabl
summari
antiinflammatori
effect
type
interferon
refer
see
text
antivir
mechan
evolutionari
pressur
may
time
mould
signal
sever
inflammatori
mechan
respond
neg
interferon
interferon
natur
task
acut
viru
infect
may
therefor
consist
inhibit
viru
replic
also
mitig
inflamm
would
inde
case
one
would
allow
think
perhap
bit
wish
interferon
suitabl
antiinflammatori
agent
use
sever
acut
viru
infect
superior
steroid
nsaid
clinic
test
done
shown
type
interferon
littl
valu
common
acut
viru
infect
howev
sever
acut
infect
caus
unusu
virus
sar
coronaviru
seem
owe
lifethreaten
sever
excess
inflammatori
reaction
document
massiv
product
certain
cytokin
huang
et
al
chemokin
law
et
al
remark
socal
cytokin
storm
appear
accompani
lowlevel
product
interferon
therapi
thank
combin
direct
antivir
natur
antiinflammatori
potenti
might
repres
prototyp
approach
manag
infect
antiinflammatori
activ
type
interferon
continu
stir
interest
clinic
investig
spectrum
diseas
amen
interferon
therapi
may
still
expand
moreov
underli
mechan
elucid
investig
may
easili
find
agent
antiinflammatori
action
similar
interferon
may
replac
type
interferon
treatment
ms
chronic
inflammatori
ill
clearli
need
thorough
investig
indepth
character
cellular
effect
review
extrem
import
make
possibl
perhap
import
expans
refin
experiment
anim
model
may
employ
strongli
underpin
antiinflammatori
potenti
type
interferon
evalu
clinic
potenti
